Loading
A phase 1/2 trial of MCLA-129, Osimertinib in non-small-cell lung cancer and small-cell lung cancer, run by Merus B.V., active and no longer recruiting.
Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination is a phase 1/2 interventional study registered as NCT04868877 by Merus B.V., with 194 participants enrolled, started 2021-04-28 and due to reach its primary completion in 2026-03. Interventions recorded: MCLA-129, Osimertinib, Chemotherapy. Conditions listed: Non-Small Cell Lung Cancer Metastatic, Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares MCLA-129, Small-cell lung cancer, Colorectal cancer, Non-small-cell lung cancer.
Shares Genmab, Head and neck squamous cell carcinoma, Small-cell lung cancer, Colorectal cancer.
Shares Genmab, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Osimertinib, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Osimertinib, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Genmab, Head and neck squamous cell carcinoma, Colorectal cancer, Non-small-cell lung cancer.
Shares Genmab, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Osimertinib, Small-cell lung cancer, Non-small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/